MUNICH and BASKING RIDGE, N.J., Aug. 21, 2019 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated results and new translational research data from two phase 1 studies evaluating investigational antibody drug conjugates (ADCs) U3-1402...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]-on-lung-cancer-300904719.html